This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Top 7 Earnings to Watch Next Week

RAD Chart RAD data by YCharts

Rite Aid (RAD)

Background: Rite Aid is a retail drugstore chain in the U.S. serving customers in numerous states across the country and in the District of Columbia. The company sells prescription drugs and a range of front-end products. Rite Aid trades an average of 3.3 million shares per day with a marketcap of $1.2 billion.

52 Week Range: $0.85 to $2.12

Book Value: $-2.90

Second quarter earnings is highly anticipated by hopeful investors expecting an improving report before the market opens on Sept. 20. The analysts' mean appraisal is presently looking for a loss of 8 cents a share, a somewhat better result compared to the loss of 12 cents during the corresponding quarter last year.

Right now, Rite Aid has 0 buy recommendations out of four analysts covering the company, three holds and one sell recommendation. The average analyst target price for Rite Aid is $1.35.

I would not be surprised if the price target gets raised after the earnings release. Walgreens (WAG) has done a great job at running circles around Rite Aid, but after following Rite Aid on and off for over a year, it appears to regaining its footing.

In the last month, the stock performed well with a 7.5% increase. Last quarter Rite Aid's earnings release was held on June 21 and the previous closing price was $1.25. Relative to a current price of $1.28, shares are up 2.4%.

The current proportion sold short based on the float is 7.5%. While 7.5% is high by normal standards, the short interest is now near the 12-month low. Bottom line, Rite Aid might blast higher from here. With a significant beat, we may witness a serious short squeeze.

4 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
TIBX $24.03 0.00%
ADBE $76.13 -0.55%
FDX $171.05 1.20%
GIS $56.06 0.02%
ORCL $44.25 1.50%

Markets

DOW 18,094.42 +56.45 0.31%
S&P 500 2,111.67 +2.75 0.13%
NASDAQ 5,053.6140 -6.6320 -0.13%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs